OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-05-24
- Target Recruit Count
- 136
- Registration Number
- NCT03896945
- Locations
- 🇺🇸
Clinical Research Site# 840-083, Lafayette, California, United States
🇺🇸Clinical Research Site# 840-094, Doral, Florida, United States
🇺🇸Clinical Research Site #840-028, Berlin, New Jersey, United States
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
- Conditions
- Schizophrenia
- Interventions
- Combination Product: Abilify MyCite®
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2021-09-05
- Target Recruit Count
- 277
- Registration Number
- NCT03892889
- Locations
- 🇺🇸
CMB Clinical Trials, Colton, California, United States
🇺🇸Excell Research, Inc, Oceanside, California, United States
🇺🇸Precise Research Centers, Flowood, Mississippi, United States
Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder
- Conditions
- Bipolar DisorderSchizophrenia
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2020-09-02
- Target Recruit Count
- 58
- Registration Number
- NCT03872596
- Locations
- 🇺🇸
Collaborative Neurosciences Network, LLC, Long Beach, California, United States
A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2020-09-02
- Target Recruit Count
- 72
- Registration Number
- NCT03854409
- Locations
- 🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸Community Clinical Research, Austin, Texas, United States
Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2021-06-15
- Target Recruit Count
- 3
- Registration Number
- NCT03850509
- Locations
- 🇺🇸
United States, California, San Carlos, California, United States
🇺🇸United States, South Carolina, Rock Hill, South Carolina, United States
🇺🇸United States, Georgia, Doraville, Georgia, United States
A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
- Conditions
- Pulmonary TB
- Interventions
- Drug: 90 mg OPC-167832Drug: RHEZDrug: 10 mg OPC-167832Drug: 3 mg OPC-167832Drug: 30 mg OPC-167832Drug: 30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQDrug: 30 mg OPC-167832 + 300 mg delamanidDrug: 30 mg OPC-167832 + 400 mg BDQ
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 122
- Registration Number
- NCT03678688
- Locations
- 🇿🇦
Satellite Site: Task at Brooklyn Chest Hospital, Cape Town, South Africa
🇿🇦University of Cape Town (Pty) Ltd., Cape Town, Mowbray, South Africa
🇿🇦TASK Clinical Research Centre, Cape Town, South Africa
Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2021-03-09
- Target Recruit Count
- 36
- Registration Number
- NCT03661983
- Locations
- 🇺🇸
Reliable Clinical Research, Hialeah, Florida, United States
🇺🇸Pediatric and Adolescent Neurodevelopment Associates, Atlanta, Georgia, United States
🇺🇸Alivation, Lincoln, Nebraska, United States
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
- Conditions
- SchizophreniaBipolar 1 DisorderMajor Depressive Disorder
- Interventions
- Combination Product: Abilify MyCite - Digital Medicine System
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2019-11-08
- Target Recruit Count
- 2
- Registration Number
- NCT03643159
- Locations
- 🇺🇸
Psychiatric Addiction Curative/PACT Atlanta LLC, Decatur, Georgia, United States
🇺🇸Kolade Research Institute, Las Vegas, Nevada, United States
🇺🇸Georgia Psychiatry and Sleep, Smyrna, Georgia, United States
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
- Conditions
- Attention Deficit DisorderAttention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 662
- Registration Number
- NCT03605849
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Culver City, California, United States
A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
- Conditions
- Attention Deficit Hyperactivity DisorderAttention Deficit Disorder
- Interventions
- Other: Placebo
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2022-03-15
- Target Recruit Count
- 604
- Registration Number
- NCT03605680
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States